Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months

Inclusion Criteria: * People aged 3-35 months; * Subject who has not been vaccinated with meningococcal group A and C conjugate vaccine, meningococcal group A polysaccharide vaccine and meningococcal group A and C and haemophilus b conjugate vaccine at the aged of 3-11 months, and who have't given boost immunity above 1 year old, and they all meet the physical examination requirements of the project; * Infants aged 3-11 months should be full-term (37-42 weeks of gestation) and their birth weight should meet the requirements (2500g ≤ body weight ≤ 4000g); * The guardian signs the informed consent form; * The guardian and his family agree to comply with the requirements of the clinical trial protocol; * Subject who had no history of other live vaccines within 14 days before vaccination and no history of other inactivated vaccines within 7 days; * Axillary body temperature ≤ 37.0 ℃. Exclusion Criteria: * History of severe allergic reactions requiring medical intervention (such as swelling of mouth and throat, dyspnea, hypotension or shock); * Have a history of allergy to the vaccine or vaccine ingredients (especially those allergic to tetanus toxoid), or have a history of other serious adverse reactions to the vaccine; * A clearly diagnosed history of thrombocytopenia or other coagulation disorders that may cause contraindications to intramuscular injection; * Abnormal production process, asphyxia rescue history, or congenital malformation, developmental disorder or serious chronic disease; * Has serious cardiovascular, liver and kidney diseases or congenital abnormalities and HIV infection; * Suffer from encephalopathy, uncontrolled epilepsy, convulsion and other progressive nervous system diseases; * Acute disease, severe chronic disease, acute attack of chronic disease and fever (axillary body temperature ≥ 38.0 ℃) in the past 3 days; * Plan to participate or be participating in any other drug clinical research; * The interval between the first dose of test vaccine and meningococcal group A polysaccharide vaccine is less than 28 days; * According to the judgment of the investigator, the subject has any other factors that are not suitable for participating in the clinical trial.